Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Seres Therapeutics Q1 2024 GAAP EPS $(0.27) Beats $(0.34) Estimate

Author: Benzinga Newsdesk | May 08, 2024 07:05am
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.34) by 20.59 percent. This is a 52.63 percent increase over losses of $(0.57) per share from the same period last year.

Posted In: MCRB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist